Insulin isophane, human


Concise Prescribing Info
Indications/Uses
DM.
Dosage/Direction for Use
Adult : SC Dose should be individualised, adjusted according to patient's response. Usual insulin requirement: 0.3-1 IU/kg/day in 1-2 divided doses.
Dosage Details
Subcutaneous
Diabetes mellitus
Adult: Usual insulin requirement: 0.3-1 IU/kg/day; may be given in 1-2 divided doses. Dose should be individualised, to be adjusted according to patient's needs. May be used alone or in combination with a fast-acting insulin.
Renal Impairment
Dosage reduction may be needed.
Hepatic Impairment
Dosage reduction may be needed.
Special Precautions
Monitor for signs of hypoglycaemia. Insulin requirements may change when there is illness, emotional disturbance or other stresses. Renal and hepatic impairment. Monitor blood glucose and haemoglobin A1c. Caution when changing insulin as changes in strength, brand, type, manufacturer and source may result in dosage changes. Inj area should be rotated to reduce the risk of lipodystrophy and inj-site reactions e.g. redness and inflammation. β-blockers may mask symptoms of hypoglycaemia. Pregnancy and lactation.
Adverse Reactions
Inj site reactions e.g. swelling, redness, itch and pain.
Potentially Fatal: Anaphylactic reactions.
IM/Parenteral/SC: B
Overdosage
Overdose may lead to hypoglycaemic attack. Mild hypoglycaemia can be treated by oral admin of glucose or sugary products. Severe attack whereby the patient has become unconscious may require treatment using IM or SC glucagon (0.5-1 mg); IV glucose must be given concurrently if patient does not respond after 10-15 minutes. Oral carbohydrate should be administered after patient regains consciousness to prevent relapse.
Drug Interactions
Concurrent use with oral antidiabetic agents, MAOIs, ACE inhibitors, salicylates, alcohol, anabolic steroids and non-selective β-blockers may reduce insulin requirements. Drugs that may increase insulin requirements include: Oral contraceptives, thiazides, thyroid hormones, growth hormone, danazol and β-sympathomimetics. Octreotide may affect insulin requirement.
Action
Description: Insulin isophane (human) is a crystalline suspension of human insulin with protamine and zinc. It is an intermediate-acting insulin. Insulin facilitates the uptake of glucose by binding to receptors on muscle and fat cells; it also inhibits glucose output from liver.
Onset: 1-2 hr.
Duration: 18-24 hr.
Pharmacokinetics:
Absorption: Takes 6-12 hr to reach peak levels.
Excretion: Urine.
Storage
Unopened vial or pen: Store at 2-8°C. Used vial and pen should be stored below 25°C; discard after 4 wk.
Disclaimer: This information is independently developed by MIMS based on Insulin isophane, human from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 MIMS. All rights reserved. Powered by MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in